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SUMMARY
Determining an adequate dose level for a drug and, more broadly, characterizing its dose response
relationship, are key objectives in the clinical development of any medicinal drug. If the dose is set
too high, safety and tolerability problems are likely to result, while selecting too low a dose makes it
diﬃcult to establish adequate eﬃcacy in the conﬁrmatory phase, possibly leading to a failed program.
Hence, dose ﬁnding studies are of critical importance in drug development and need to be planned
carefully. In this paper we focus on practical considerations for establishing eﬃcient study designs to
estimate target doses of interest. We consider optimal designs for both the estimation of the minimum
eﬀective dose (MED) and the dose achieving 100p% of the maximum treatment eﬀect (EDp). These
designs are compared with D-optimal designs for a given dose response model. Extensions to robust
designs accounting for model uncertainty are also discussed. A case study is used to motivate and
illustrate the methods from this paper. Copyright c© 2000 John Wiley & Sons, Ltd.
key words: dose ﬁnding, robust designs, model uncertainty, minimum eﬀective dose, dose response,
target dose estimation, sample size
1. Introduction
Determining an adequate dose level for a drug and, more broadly, characterizing its dose
response relationship, are key objectives in the clinical development process of any medicinal
drug. If the dose is set too high, safety and tolerability problems are likely to result, while
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selecting too low a dose makes it diﬃcult to establish adequate eﬃcacy in the conﬁrmatory
phase. There are varying degrees of consequences associated with selecting a “wrong” dose
level for a new compound. For example, it may be that only after having marketed a speciﬁed
dose of a drug it becomes apparent that the level was set too high. This phenomenon has
been documented by the U.S. Food and Drug Administration (FDA), who reported that
approximately 10% of drugs approved between 1980-1989 have incurred dose changes - mostly
decreases - of greater than 33% [1]. Alternatively, the compound may fail regulatory approval
due to an unacceptably high risk/beneﬁt ratio. In such a setting two losses will result: (i)
patients will never receive the incremental (or potentially ground-breaking) advancement in
medical treatment and (ii) the missed opportunity results in substantial ﬁnancial losses for
the pharmaceutical company who has developed the drug. The selection of the dose level(s) to
be brought into the ﬁnal conﬁrmatory clinical studies, and hence for potential release on the
market, is thus a key decision step involving inherent serious ethical and ﬁnancial consequences.
For a recent general discussion of issues and challenges arising in clinical dose ﬁnding studies
we refer to [2].
An indication of the importance of properly conducted dose response studies is the early
publication of the ICH E4 guideline [3], which is the primary source of regulatory guidance in
this area. The guideline states in its introductory section that the purpose of dose response
information is “to ﬁnd the smallest dose with a discernible useful eﬀect or a maximum dose
beyond which no further beneﬁcial eﬀects is seen, but practical study designs do not exist to
allow for precise determination of these doses”. Note that the ICH E4 guideline stresses the
importance of obtaining good dose response information by estimating relevant target doses.
The smallest dose with a discernible useful eﬀect is often characterized as the minimum eﬀective
dose (MED), that is, the smallest dose producing a clinically important response that can be
declared statistically signiﬁcantly diﬀerent from the placebo response [1]. Several methods exist
to estimate the MED using either modeling approaches [4, 5] or multiple test strategies [6, 7].
The maximum useful dose, beyond which no further beneﬁcial eﬀects is seen, can similarly
be estimated using multiple test strategies [8] or modeling approaches when estimating the
smallest dose achieving 100p% of the maximum treatment eﬀect in the observed dose range
(EDp, 0 < p < 1) [9].
As suggested by the quote above from the ICH E4 guideline, study designs that allow
for precise estimation of relevant target doses are hard to derive and, if available, often not
applied in clinical practice. In this article we focus on the design of clinical dose ﬁnding studies
to produce the information needed to eﬃciently and reliably characterize the beneﬁt of a drug
over a dose range of interest. In particular, we consider eﬃcient designs for estimating target
doses of interest (i.e, either the MED or an EDp). Given a ﬁxed number of patients available
for the conduct of a clinical dose ﬁnding study, we determine the necessary number of diﬀerent
dose levels, the location of the dose levels within the dose range, and the proportions of patients
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to be allocated to each of the dose levels, such that the asymptotic variance of the target dose
estimate is minimized.
In practice, the results in this paper can be used in at least two distinct ways. First, relative
eﬃciencies can be calculated for practically feasible designs. Clinical teams can then balance
the additional ﬁnancial and logistical costs potentially associated with the resulting optimal
designs (due to a larger total number of dose levels, the need for producing additional dose levels
not considered in the previous studies, etc.) against the beneﬁt of an increased information
value resulting from the larger precision in the target dose estimation. The relative eﬃciencies
based on are directly translated into relative sample size requirements and are thus easy
to communicate to the clinical teams and decision boards. Second, asymptotic conﬁdence
intervals for the target dose can be constructed, which give a quantiﬁable information on the
uncertainty about the target dose estimate estimate under a particular dose response model.
In fact, current practice dictates that the sample sizes for clinical dose ﬁnding studies are
calculated based on power calculations to detect dose response. The resulting sample sizes,
however, are often inappropriate for estimating a target dose with a reasonable precision. Pre-
specifying the width of the conﬁdence interval for the target dose and calculating backwards
the necessary sample sizes to achieve the required precision thus puts current practices into
a diﬀerent perspective. Even if the resulting sample sizes of such an approach might not be
realistic, the results in this paper can be used to quantify the uncertainty about the target
dose estimate, so that the decision makers can balance better the costs and risks based upon
the available information.
In the remainder of this paper we formalize the ideas presented in this section and emphasize
practical considerations. In Section 2 we describe a case study to put the subsequent discussion
into a practical context. In Section 3 we discuss optimal designs to estimate either the MED or
an EDp. These designs are then compared with D-optimal designs, which minimize the volume
of the conﬁdence ellipsoid for the dose response model parameters. Finally, we robustify these
designs with respect to the underlying true, but unknown dose response model. Practical
considerations of these results are discussed when re-visiting the case study in Section 4.
Concluding remarks are given in Section 5.
2. A dose ﬁnding study for an anti-asthmatic drug
This example refers to a real clinical study in Phase II for the asthma indication. The primary
objective of the trial is to select a dose for the Phase III (conﬁrmatory) program. Several active
dose levels plus a placebo arm are to be used in the trial, with patients being randomized to
one of the treatments (parallel group design). Patients receive one daily dose of their assigned
treatment for a total of 14 days. The primary eﬃcacy endpoint of the study is the change
from baseline (i.e., the ﬁrst visit) in the forced expiratory volume measured over one second,
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FEV1, at the end of the study. A placebo eﬀect of 60 mL is assumed with a maximum expected
treatment eﬀect increase over placebo of 280 mL and a standard deviation of σ = 350 mL. The
clinically relevant beneﬁt over the placebo eﬀect is set to Δ = 200 mL. That is, an increase in
treatment eﬀect of less than 200 mL over the placebo response is considered to be clinically
irrelevant.
At the time of designing the study, the clinical team was unsure about the true dose
response shape and could in particular not rule out a non-monotonic proﬁle (for example,
an umbrella shape). After discussions with the clinical team, several dose response models
with associated shapes were identiﬁed as plausible to describe the data at study end. The full
model speciﬁcations of the candidate dose response models are given in Table I and displayed
graphically in Figure 1. We refer to [4, 10] for details on the use of candidate models in dose
response studies and the elicitation of best guesses for the model parameters.
Model Full model speciﬁcation
Linear 60 + 0.56d
Beta 60 + (7/2250)d(600− d)
Emax1 60 + 294d/(25 + d)
Emax2 60 + 340d/(107.14+ d)
Logistic 49.62 + 290.51/ {1 + exp[(150− d)/45.51]}
Table I. Candidate dose response models as a function of dose d.
From Figure 1 the uncertainty about the true, but unknown dose response model at the
design stage of the study becomes evident. Essentially the entire space of potential dose
response shapes is covered by the current selection of candidate models, including two diﬀerent
parameter speciﬁcations for the Emax model and the inclusion of an umbrella shape (through
the Beta model) to cover a potential down-turn in eﬀect at larger doses. The potential impact
of the model uncertainty becomes clear, when comparing the associated MED for each of the
ﬁve candidate model shapes. For illustration purposes, the clinical relevance threshold Δ is
included in Figure 1 (horizontal dashed line), together with the resulting MED. For example,
for the ﬁrst Emax model the MED is 53.2 μg, whereas the MED is 357.1 μg if the linear model
is true. Specifying a single dose response model in the study protocol (with the aim to either
determine the experimental design or to specify the ﬁnal analysis) is thus not possible given
the uncertainty about the true model and the potential impact on the study outcome.
Given the information and constraints described above, the clinical team was then faced
with the decision of how many dose levels k to include in the study, which dose levels d1, . . . , dk
to investigate, whether to use an unbalanced allocation of the patients to the dose levels di,
and how to determine the total sample size n. In the following section we discuss methods to
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Figure 1. Dose response models corresponding to the models in Table I. Open dots indicate the four
active dose levels – 62.5, 125, 250, and 500 μg – plus a placebo arm ﬁnally used in the clinical study.
address these questions and apply the results when re-visiting the case study in Section 4.
3. Eﬃcient designs for target dose estimation
In this section we consider optimal designs for both the estimation of the MED and the EDp.
These designs are compared with D-optimal designs for a given dose response model. We
use the Emax to illustrate the various designs, although the results can be extended to other
common dose response models, such as those shown in Table I. Extensions to robust designs
accounting for model uncertainty are also discussed.
3.1. Notation
We consider the non-linear regression model
Yij = f(di, ϑ) + εij , (1)
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where Yij denotes the response of patient j at dose di, i = 1, . . . , k, j = 1, . . . , ni, f(.)
denotes the true, but unknown dose response model determined through the parameter vector
ϑ = (ϑ0, ϑ1, ϑ0)T = (ϑ0, ϑ1, . . . , ϑ)T ∈ R+1, and εij denote the residual errors, which are
assumed to be independent normal distributed with common variance σ2. Example model
speciﬁcations for the function f(d, ϑ) are given in Table I.
As mentioned in the Introduction, we consider in this article two diﬀerent target doses, the
MED and the EDp, which are introduced formally now. Let d (d) denote the lowest (highest)
dose within the dose range [d, d] under investigation, where often d = 0 is the placebo dose.
For a given clinically relevant eﬀect Δ, the MED associated with a model f(d, ϑ) is deﬁned as
MED = inf{d ∈ (d, d] : f(d, ϑ) ≥ f(d, ϑ) + Δ}.
Note that the MED does not need to exist, as no dose in (d, d] may produce an improvement of
Δ over f(d, ϑ). We restrict the MED to lie within the interval (d, d] in order to avoid problems
arising from extrapolating beyond the dose range under investigation. Following [10], we use
M̂ED = inf{d ∈ (d, d] : f(d, ϑˆ) ≥ f(d, ϑˆ) + Δ, Ld > f(d, ϑˆ)}
to estimate the MED, where Ld denotes the lower 1 − γ conﬁdence bound for the expected
value f(d, ϑˆ) at dose d and ϑˆ denotes the non-linear least squares estimate of ϑ.
Let h(d, ϑ) = f(d, ϑ) − f(d, ϑ) denote the eﬀect diﬀerence at the doses d ∈ (d, d] and d.
Following [2], the EDp can then be deﬁned as
EDp = inf
{
d ∈ (d, d] : h(d, ϑ)
h(dmax, ϑ)
≥ p
}
,
where dmax = argmaxd∈(d,d]h(d, ϑ) denotes the dose corresponding to the maximum eﬀect
diﬀerence in the interval (d, d]. Unlike the MED, the EDp always exists. If L′d denotes the
lower 1 − γ conﬁdence bound for the expected value h(d, ϑ) at dose d, we can estimate EDp
by
ÊDp = inf
{
d ∈ (d, d] : h(d, ϑˆ)
h(dˆmax, ϑˆ)
≥ p, L′d > 0
}
,
where dˆmax = argmaxd∈(d,d]h(d, ϑˆ).
Finally, let
ξ =
(
d1 . . . dk
w1 . . . wk
)
denote an experimental design with relative allocation wi of patients at doses di, i = 1, . . . , k.
Following [11], the weights wi ≥ 0, with
∑k
i=1 wi = 1, are not necessarily multiples of 1/n,
where n denotes the total sample size. In practice, for a given sample size n, a design
ξ is implemented by rounding the quantities win to integers, say ni, with
∑k
i=1 ni =
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n (approximate design theory). We denote by M(ξ, ϑ) =
∑k
i=1 wig(di, ϑ)g
T (di, ϑ) the
information matrix of the design ξ in the regression model (1), where
gT (d, ϑ) =
∂f(d, ϑ)
∂ϑ
=
(
1, f0(d, ϑ0), ϑ1
∂f0(d, ϑ0)
∂ϑ2
, . . . , ϑ1
∂f0(d, ϑ0)
∂ϑ
)
∈ R+1
denotes the gradient of the response function f with respect to the parameter vector ϑ. The
matrix M(ξ, ϑ) can be interpreted as a measure of precision of the parameter estimate ϑˆ based
on the design ξ. “Larger” values of M(ξ, ϑ) indicate better (i.e., more precise) estimates of ϑˆ.
3.2. Optimal designs for MED estimation
Using Elfving’s theorem [12], Dette et al. [13] investigated optimal designs to estimate the
MED for several practical relevant dose response models. They derived general results, but
omitted some of the explicit expressions for the individual models. In the following we derive
the necessary expressions for the situations considered in the present paper. To keep the
discussion concrete, we focus on the Emax model
f(d, ϑ) = ϑ0 + ϑ1
d
ϑ2 + d
(2)
to illustrate the concepts. In the Emax model (2), ϑ0 denotes the placebo eﬀect at dose d = 0, ϑ1
denotes the asymptotic maximum treatment eﬀect achieved at an inﬁnite dose, and ϑ2 denotes
the ED50, i.e., the dose that gives 50% of the maximum treatment eﬀect [4, 14]. The motivation
to focus on the Emax model is its ubiquitous use in clinical practice. In particular, the Emax
can be justiﬁed on the relationship of drug-receptor interactions and therefore deduced from
the chemical equilibrium equation [15].
We consider ﬁrst the gradient
g(d, ϑ) =
(
1,
d
d + ϑ2
,
−ϑ1d
(d + ϑ2)2
)T
of f(d, ϑ) with respect to ϑ for the Emax model (2). Figure 2 plots the partial derivatives
as a function of the dose d for the two Emax models speciﬁed in Table I. The Emax1 model,
which has the smaller ϑ2 (= ED50) value and the steeper increase to the plateau level, has
considerably larger values for the ﬁrst derivatives at smaller doses than the Emax2 model. This
will be reﬂected when calculating optimal designs, which account for the dose ranges with the
potential largest amount of information.
The variance of the MED-estimate M̂ED for a general dose response model f is given by
σ2ΨMED(ξ)/n, where ΨMED(ξ) = bT (ϑ0, . . . , ϑ)M−(ξ, ϑ)b(ϑ0, . . . , ϑ) and the vector b denotes
the gradient of the function f−1
(
Δ
ϑ1
+ f(d, ϑ)
)
with respect to ϑ [13]. For the Emax model (2)
b(ϑ0, ϑ1, ϑ2) = − r(ϑ2 + d)(rd− ϑ2(r − 1))2
(
0,
ϑ2
ϑ1
(d + ϑ2), (r − 1)ϑ2 + d(1 + r)
)T
,
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Figure 2. Partial derivatives for the two Emax models speciﬁed in Table I. Left plot: d/(d + ϑ2); right
plot: −ϑ1d/(d + ϑ2)2. Solid line: Emax 1 model; dotted line: Emax 2 model
where r = Δ/ϑ1. A design ξ∗MED is called MED-optimal if it minimizes ΨMED(ξ) among all
designs ξ for which the MED is estimable. Such optimal designs can be calculated explicitly
for common dose response models with +1 = 2 or 3 model parameters; otherwise, numerical
optimization methods have to be used [13]. For the Emax model (2), for example, the optimal
design ξ∗MED is either a two point design or a three point design, depending on – loosely
speaking - the relative position of the MED: If the Emax model increases steeply at smaller
doses and the threshold Δ is small, two points are not suﬃcient to guarantee a precise MED
estimate. It is noteworthy that if a two-point design is optimal for the Emax model, the non-
trivial support point matches exactly the expected MED. Consequently, the optimal designs
for the two Emax models speciﬁed in Table I are given by
ξ∗MED(Emax 1) =
(
0 53.19
0.5 0.5
)
and ξ∗MED(Emax 2) =
(
0 153.06
0.5 0.5
)
.
Note that the second support point d2 is considerably smaller for the Emax 1 model than for
the Emax2 model, which is also consistent with Figure 2. In practice, a two-point design will
not be suﬃcient to estimate an Emax model, which has  = 3 parameters and thus requires at
least three support points. In such situations we recommend to use a slight modiﬁcation of the
optimal design by allocating a small fraction of patients to an additional dose. In the previous
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example, one could use
ξ˜∗MED(Emax1) =
(
0 53.19 500
0.45 0.45 0.1
)
and ξ˜∗MED(Emax 2) =
(
0 153.06 500
0.45 0.45 0.1
)
instead of ξ∗MED(Emax1) and ξ
∗
MED(Emax 2), respectively.
Extending the results from [13], one can derive analytical expressions for the variance of
the MED-estimate under an optimal design ξ∗MED. For the Emax model one obtains
ΨMED
(
ξ∗MED
)
=
4ϑ22(d1 + ϑ2)
4
ϑ21(ϑ2 − r(d1 + ϑ2))4
if the optimal design is a two-point design and
ΨMED
(
ξ∗MED
)
=
82r2(d1 + ϑ2)6(d3 + ϑ2)2((d1 − d3)ϑ2 + (d1 + d3)rϑ2 + (d1d3 + ϑ22)r)2
ϑ22ϑ
2
1(d3 − d1)4(rd1 + (r − 1)ϑ2)2
if the optimal design is a three point design. Applying these formulas to our numerical example
from Table I, this gives ΨMED
(
ξ∗MED
)
= 2.77 for the Emax1 model and ΨMED
(
ξ∗MED
)
= 13.82
for the Emax2 model.
In fact, we can not only establish the expected variance of the MED estimate using the
expressions above, but also calculate an (asymptotic) conﬁdence interval for the MED. Relying
on the large sample normal approximation, we have[
M̂ED− z1−α2 σˆ
√
ΨMED(ξ)
n
; M̂ED + z1−α2 σˆ
√
ΨMED(ξ)
n
]
, (3)
where z1−α/2 denotes the 1−α/2 quantile of the standard normal distribution. Optimal designs
ξ∗MED, which minimize ΨMED(ξ), consequently minimize the expected width of the conﬁdence
interval for the MED. If we plug in the expected standard deviation of σ = 350 from Section
2, set α = 0.05 and assume a total of n = 100 patients, we obtain the expected conﬁdence
intervals [−60.92; 167.32] for the Emax1 model and [−101.89; 408.09] for the Emax 2 model. As
expected from the previous discussions, the Emax1 model provides a more precise estimate
of the MED estimate than the the Emax 2 model, since it is considerably steeper around the
expected MED. Note, however, the large width of the expected conﬁdence interval, which in
case of the Emax2 model covers almost the entire dose range under investigation if only 100
patients were used in total. In Section 4 we discuss how to calculate the necessary sample size
for a dose ﬁnding study to meet a pre-speciﬁed precision of the MED estimate based on the
expected width of the conﬁdence interval in (3).
3.3. Optimal designs for EDp estimation
We now consider optimal designs to estimate the EDp for a given 0 < p < 1. Similar as for the
MED estimation problem, the variance of the EDp-estimate ÊDp for a general dose response
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Prepared using simauth.cls
10 BRETZ ET AL.
model f is given by σ2ΨEDp(ξ)/n, where ΨEDp(ξ) = cT (ϑ0, . . . , ϑp)M−(ξ, ϑ)c(ϑ0, . . . , ϑp),
M(ξ, ϑ) is as deﬁned in Section 3.1, and the vector c denotes the gradient of the function
f−1(f(d, ϑ)+p(f(dmax, ϑ)−f(d, ϑ))) with respect to ϑ. A design ξ∗EDp is called EDp-optimal if
it minimizes ΨEDp(ξ) among all designs ξ. Using Elfving’s theorem [12], such optimal designs
can be calculated analytically for common dose response models with  + 1 = 2 or 3 model
parameters; otherwise, numerical optimization methods have to be used. It can be shown that
the vector c(ϑ) does not depend neither on ϑ0 nor on ϑ1 and consequently is of the form
c(ϑ) = γ(0, 0, c1, . . . , c−1)T for a same constant γ. For example, in the Emax model we have
c(ϑ) =
p(1− p)(d− d)2
(ϑ2 + pd + (1− p)d)2
(0, 0, 1)T .
This implies that for dose response models with +1 = 3 parameters the EDp-optimal designs
do not depend on p.
As for the MED estimation problem, we use the Emax model (2) to illustrate the explicit
expressions. The optimal design ξ∗EDp for the Emax model is given by
ξ∗EDp =
(
d1 d(ϑ) d3
0.25 0.5 0.25
)
,
where the dose level d(ϑ) is deﬁned by
d(ϑ) =
ϑ2d + ϑ2d + 2dd
2ϑ2 + d + d
. (4)
It is noteworthy that the EDp-optimal design (4) does not depend on the particular value p
and that the support points coincide with those of the MED-optimal design in the case where
this optimal design has three dose levels. Applying (4), the optimal designs for the two Emax
models speciﬁed in Table I are given by
ξ∗EDp(Emax 1) =
(
0 22.727 500
0.25 0.5 0.25
)
and ξ∗EDp(Emax 2) =
(
0 74.999 500
0.25 0.5 0.25
)
for any 0 < p < 1. Note that the second support point d2 is considerably smaller for the
Emax 1 model than for the Emax2 model, which is consistent with the previous ﬁndings for the
MED estimation problem. Although the EDp-optimal design does not depend on the speciﬁc
value of p, this quantity enters in the asymptotic variance of the EDp-estimate ÊDp under the
EDp-optimal design ξ∗EDp , which is given by
ΨEDp
(
ξ∗EDp
)
=
(
8p(1− p)(ϑ2 + d1)2(ϑ2 + d3)2
ϑ1ϑ2(ϑ2 + pd1 + (1− p)d3)2
)2
.
Figure 3 plots ΨEDp
(
ξ∗EDp
)
as a function of p for the two Emax models speciﬁed in Table I.
The Emax 1 model, which has the smaller ϑ2 (= ED50) value and the steeper increase to the
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plateau level, leads to considerably smaller variances of ÊDp than the Emax2 model for most
p ∈ (0, 1). Recall from Section 3.2 the values ΨMED
(
ξ∗MED
)
= 2.77 for the Emax1 model and
ΨMED
(
ξ∗MED
)
= 13.82 for the Emax2 model. Thus, the MED is estimated with larger variance
under the MED-optimal design than the EDp under the EDp-optimal design for the Emax2
model for all p ∈ (0, 1). The same is also true the Emax1 model for p < 0.75. Note that the
maximum value of ΨEDp
(
ξ∗EDp
)
is numerically the same for both Emax models in Figure 3.
Finally we note that asymptotic conﬁdence intervals for the EDp can be constructed similarly
to equation (3) for the MED.
0.0 0.2 0.4 0.6 0.8 1.0
0
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)
Figure 3. The function ΨEDp
(
ξ∗EDp
)
for the two Emax models speciﬁed in Table I. Solid line: Emax 1
model; dotted line: Emax 2 model. The asymptotic variance of ÊDp under the EDp-optimal design ξ
∗
EDp
is given by σ2ΨEDp
(
ξ∗EDp
)
/n
3.4. D-optimal designs for dose response estimation
In the previous sections we used c-optimal designs to minimize the variance of a target dose
estimate (either the MED or an EDp). Often it is argued that the optimal designs for one target
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dose might be very ineﬃcient for another target dose. Instead, D-optimal designs are proposed
in the context of dose response studies, which focus on minimizing simultaneously the variance
for all model parameter estimates [16, 17]. D-optimal designs operate on the determinant of
the information matrix M(ξ, ϑ) and minimize the volume of the conﬁdence ellipsoid for the
dose response model parameters, thus focusing on the entire dose response relationship instead
of a single dose.
Closed form expressions can often be derived by standard arguments using the equivalence
theorem for the D-optimality criteria [18]. For example, it can be shown that for the Emax
model the D-optimal design has equal weights at three points, which coincide with the support
points of the EDp-optimal design [19]. Similar results hold also for the other models in Table I
with  ≤ 3 parameters. This indicates that for these models the D-optimal designs are rather
eﬃcient to estimate the EDp and vice versa. It follows from [19] that the D-optimal design ξ∗D
for the Emax model (2) is given by
ξ∗D =
(
d1 d(ϑ) d3
0.3 0.3 0.3
)
,
where the dose level d(ϑ) is deﬁned in (4). Consequently, the D-optimal designs for the two
Emax models speciﬁed in Table I are given by
ξ∗D(Emax 1) =
(
0 22.727 500
0.3 0.3 0.3
)
and ξ∗D(Emax 2) =
(
0 74.999 500
0.3 0.3 0.3
)
.
As mentioned above, the support points of the EDp- and D-optimal designs coincide, and
it would be of interest to investigate the relative eﬃciencies between these two and the MED-
optimal design. Relative eﬃciencies are proportional to the sample size needed for a given
design ξ to achieve the same precision for parameter estimation as a reference designs, e.g., an
optimal design ξ∗ in our case. If, for example, the relative eﬃciency of ξ versus ξ∗ is 0.5, then
the optimal design ξ∗ would need only half of the patients to achieve the same precision (e.g.,
for the MED or EDp estimation) as a given design ξ. Consequently, in case of MED or EDp
estimation, the optimal design ξ∗ would lead to 30% shorter conﬁdence intervals than a given
design ξ. For our purposes, the relative eﬃciencies are deﬁned by
eﬀD(ξ) =
( | M(ξ, ϑ) |
| M(ξ∗D, ϑ) |
)1/3
,
eﬀEDp(ξ) =
Ψ∗EDp(ξEDp)
ΨEDp(ξ)
,
eﬀMED(ξ) =
Ψ∗MED(ξMED)
ΨMED(ξ)
.
In Table II we use the Emax 1 model to show the eﬃciencies of the diﬀerent designs for the
diﬀerent estimation problems; the eﬃciencies for the Emax2 model are similar and therefore
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omitted. Note that the MED-optimal design is supported at only two points and does not allow
the estimation of all model parameters. We therefore use the slightly modiﬁed ξ˜∗MED(Emax 1)
from Section 3.2, which allocates 10% of the patients to the highest dose. We observe reasonable
D- and EDp-eﬃciencies for the EDp- and D-optimal design, respectively. The MED-eﬃciencies
for these designs are 66% and 73%. On the other hand, the MED-optimal design has a rather
poor performance to estimate the EDp.
Design Relative eﬃciency
eﬀD(ξ) eﬀEDp(ξ) eﬀMED(ξ)
ξ∗D 1 0.8889 0.7334
ξ∗EDp 0.9449 1 0.6587
ξ˜∗MED 0.7142 0.3551 0.9401
Table II. Relative eﬃciencies of D-, EDp- and MED-optimal designs for the Emax 1 model.
3.5. Robust designs
All the designs considered so far are locally optimal in the sense that they are constructed
for a particular dose response shape. That is, the optimality of a design ξ∗ holds for the dose
response model f and associated parameter vector ϑ, for which it is constructed. Dette et al.
[13] investigated the robustness of MED-optimal designs with respect to their assumptions.
Their results suggests that locally optimal designs are moderately robust with respect to a
misspeciﬁcation of the model parameters, but highly sensitive with respect to a misspeciﬁcation
of the regression function.
In practice, we recommend for any type of estimation problem the use of model robust
designs introduced below, which are less sensitive with respect to the choice of the regression
model. The following considerations are generic and hold for robustifying either MED-, EDp-,
or D-optimal designs considered in the previous sections. The key idea is to assume m regression
models f1(d, ϑ(1)), . . . , fm(d, ϑ(m)), calculate optimal designs for each of these models using
the methods above and ﬁnally aggregate the information to construct a robust design. In the
following we apply two generic approaches from the literature [20, 21, 22] to the estimation
problems considered here. The relative performance of both types of robust design will be
illustrated when re-visiting the case study in Section 4. Since the results are generic, we
drop in the following the subscripts indicating whether MED-, EDp-, or D-robust designs
are considered.
We ﬁrst consider maximin designs, which maximize the minimum eﬃciency of a given design
relative to the optimal designs for the m regression models under investigation. That is, given
the m regression functions fj(d, ϑ(j)) with associated optimal designs ξ∗j , j = 1, . . . ,m, a
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design is called maximin optimal if it maximizes min{eﬀ1(ξ), . . . , eﬀm(ξ)} among all designs ξ,
where eﬀj(ξ) denotes the eﬃciency of a design ξ in the jth model (j = 1, . . . ,m) with respect
to the optimal design for the model under consideration. The maximin design can therefore
be thought of as safeguarding against the worst case scenario, since the minimum relative
eﬃciency is maximized. An alternative approach is to assign probabilities α1, . . . , αm with∑m
j=1 αj = 1 to each of the m regression models and subsequently to maximize the weighted
sum
∑m
j=1 αj log eﬀj(ξ), leading to so-called Bayesian optimal designs. The model probabilities
may reﬂect the clinical team believes about the importance or likelihood for a particular model.
If no prior information is available and all models are equally relevant, a reasonable choice is to
use equal weights α1 = . . . = αm = 1/m. Note that response-adaptive designs could be used,
where data of an ongoing clinical study is used to update the prior information about the
weights αj in order to calculate a Bayesian optimal design for subsequent cohorts of patients.
Such ﬂexibility is not available for maximin designs.
4. Application to case study
We now revisit the case study from Section 2 to apply some of the results from the previous
section. For simplicity, we keep the discussion focused on estimating the MED, since the
considerations below apply equally to other problems, including the results for EDp- and D-
optimal designs from Section 3.
Recall from Section 2 that the main open questions at the design stage of the study under
investigation are the number k of dose levels, the choice of the dose levels d1, . . . , dk, whether
to use an unbalanced allocation of the patients to the dose levels di or not, and the total
sample size n. Given the inherent model uncertainty problem, we calculate both maximin and
Bayes designs based on the m = 5 dose response models speciﬁed in Table I. Since no model
is assumed to be more likely than others, equal prior weights αi = 1/5 are assigned to each of
the models. Note that in practice the choice of the dose levels to be investigated in a clinical
study is often restricted by manufacturing or other constraints. That is, not all doses from
the continuous interval [d, d] can be investigated in a clinical study. In the current study, such
logistical considerations let the clinical team to randomize the patients to the four active dose
levels 62.5, 125, 250, and 500 μg plus a placebo (denoted in the following as actual dose levels;
they are indicated by the open dots in Figure 1). Since restricting the space of admissible doses
has an impact on the choice of the ﬁnal design and its eﬃciency, we consider below both the
unrestricted and the restricted case. To be more speciﬁc, we consider maximin and Bayesian
optimal designs for the following scenarios:
(A) Unrestricted search for a robust design over the continuous interval [d, d] = [0, 500]
(B) Restricted search for a robust design given the actual dose levels 0, 62.5, 125, 250, and
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500 μg
(C) Restricted search for a robust design given the dose levels from (A)
Note that for scenarios (B) and (C) the design search is restricted in determining the allocation
ratios wi for the given doses.
Table III provides the results from the calculations for the total of six diﬀerent cases.
Consider ﬁrst the maximin designs in the upper half of Table III. Allowing for an unrestricted
design search in [d, d] in scenario (A), the maximin design is a ﬁve-point design, which allocates
roughly 36%, 20%, 22%, 6% and 16% of the patients to the dose levels 0, 49, 177, 452 and 500
μg, respectively. The eﬃciency of the maximin design relative to the optimal designs for each
of the models under consideration is given in the right column of Table III. If we restrict the
design search to the actual dose levels, we obtain the results given under scenario (B). Note that
the relative eﬃciencies of the design under scenario (B) are uniformly better than those under
scenario (A). This might look counterintuitive at ﬁrst sight, since under scenario (B) we are
restricting the design space considerably by specifying the ﬁve dose levels. One might assume
that such restriction would lead to inferior designs as compared to scenario (A). Note, however,
that the maximin designs depend on the individual optimal designs, which are diﬀerent under
(A) and (B). More precisely, the eﬃciencies under scenario (A) are calculated with respect
to the optimal designs for the individual models on the unrestricted design space [d, d], while
under scenario (B) only designs with the actual dose levels are considered. Consequently, the
resulting designs under scenarios (A) and (B) might not be ordered with respect to their
eﬃciencies as could be expected otherwise. This is also true under scenario (C): If the ﬁve
given dose levels were the only feasible ones, we would obtain a maximin design, which has
larger eﬃciencies than those under scenarios (A) and (B) because these are calculated in the
class of designs with only four dose levels. Consider now the Bayesian designs in the lower half
of Table III. We observe that that the Bayesian designs yield larger eﬃciencies for the Beta,
Emax and Logistic model, while the smallest eﬃciency is obtained in the linear model. It is also
noteworthy that in the Bayesian case the designs derived under scenario (A) and (C) coincide.
We now focus on the the remaining question about the total number of patients to be
included in the dose ﬁnding study. Current practice suggests to base the sample size calculation
on some power calculation to detect a true treatment eﬀect [23]. Broadly speaking, the
responses at the diﬀerent dose levels di are ﬁxed and the probability to achieve a signiﬁcant
dose response signal at study end is calculated for a given suitable test procedure. Another
approach is to focus on the dose estimation problem, using a pre-speciﬁed minimum precision
for the target dose estimate to calculate the sample size, as discussed now.
One possibility to quantify the precision is to pre-specify the expected width of a conﬁdence
interval for the target dose estimate of interest, such as given in (3) for the MED estimation
problem, and by backward calculation determine the number n of patients required to achieve
this expected value. Assume, for example, that the Emax1 model speciﬁed in Table I is the
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Scenario Design speciﬁcation Relative eﬃciencies
d1, w1 d2, w2 d3, w3 d4, w4 d5, w5 Linear Beta Emax 1 Emax 2 Logistic
Maximin design
(A) 0 47.66 176.82 452.21 500 0.5727 0.5727 0.5727 0.6755 0.5727
0.356 0.197 0.224 0.056 0.167
(B) 0 62.5 125 250 500 0.6097 0.6097 0.6097 0.6097 0.6663
0.286 0.236 0.134 0.103 0.241
(C) 0 47.66 176.82 452.21 500 0.6315 0.6315 0.6315 0.6853 0.6315
0.318 0.259 0.178 0.009 0.236
Bayesian design with αi = 0.2
(A) 0 45.86 182.1 433.63 500 0.4494 0.6091 0.5921 0.6990 0.7247
0.384 0.192 0.270 0.035 0.119
(B) 0 62.5 125 250 500 0.4674 0.5706 0.7635 0.7763 0.7543
0.322 0.181 0.197 0.144 0.156
(C) 0 45.86 182.1 433.63 500 0.4494 0.8962 0.6092 0.8193 0.8092
0.384 0.192 0.270 0.035 0.119
Table III. Left column: Maximin (top) and Bayesian (bottom) designs for several scenarios (details
given in the text). Right column: Relative eﬃciencies compared to the optimal designs for each model
from Table I.
true underlying model and that we consider applying the optimal design ξ∗MED(Emax1) from
Section 3.2. If we require the width of the expected conﬁdence interval for the MED estimate
to be less or equal than 100 μg (and thus cover 20% of the dose range under investigation),
then n = 520 patients are necessary, which are allocated according to the weights wi = ni/n
determined by ξ∗MED(Emax 1). While such an approach is helpful to communicate the idea of
justifying a sample size based on a pre-speciﬁed precision, in practice the resulting conﬁdence
intervals are likely to be wider because of model uncertainty. Bootstrap methods can be used
to obtain conﬁdence intervals, which account for this additional variability.
Another possibility to quantify the precision is to simulate a large number of clinical trials
based on the initial assumptions, estimate the target dose at each simulation run, and report
the resulting empirical distribution of the dose estimates. To illustrate such an approach,
Figure 3 displays the histograms of MED estimates for the dose response models speciﬁed in
Table I based on 230 observations allocated equally to the actual dose levels and applying the
MCP-Mod procedure [10]. Note that for these plots the estimated MED values were rounded
to the next dose investigated in the study. Clearly, there is considerable variability in the
estimated values, depending on the true dose response shape, how well the true MED is
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captured by the doses under investigation, the total sample size and its allocation, etc. We
believe that considerations like those described here help the clinical teams to better compare
diﬀerent experimental designs and understand the implications of the individual options.
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Figure 4. Histograms of MED estimates for the dose response models speciﬁed in Table I. Horizontal
lines indicate the position of the true MED under a particular model.
5. Discussion
In this paper we summarized MED-, EDp- and D-optimal designs for common classes
of dose response models. The results can be extended to other estimation problems and
regression models. The asymptotic designs have generally good ﬁnite sample properties and are
moderately robust with respect to an initial misspeciﬁcation of the model parameters. However,
the designs are considerably sensitive to a misspeciﬁcation of the dose regression model. If a
clinical team decides to apply a local optimal design for a particular dose response model, it
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should be aware of the inherent risks, in case that the true underlying dose response model
is diﬀerent to the assumed one. If the information on the dose response model is too vague,
robust designs based on maximin or Bayesian optimality criteria are a viable alternative. Other
approaches exist as well to minimize the impact of model uncertainty. Discrimination designs
have been investigated, which allow for a diﬀerentiation between several non-linear regression
models [24, 25]. Response-adaptive designs allow for interim looks during an ongoing study,
use the accumulated information to correct the initial assumptions and design the subsequent
stages of the trial accordingly [17, 26, 27]. Future research will be devoted to apply these
methods and compare the results with those obtained here.
However the decision on the ﬁnal study design looks like, we believe that a careful
investigation of its properties at the planning stage is essential. In this paper we focused on
some of the related practical considerations. Computing relative eﬃciencies for diﬀerent design
options and having a basic notion about the expected precision for the estimation problem
will help to understand the inherent implications. With such tools, clinical study designs can
be tailored to the speciﬁc study objectives and consequently guarantee a higher chance for a
successful outcome.
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